Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Growth in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 120,600 shares, an increase of 100.7% from the February 28th total of 60,100 shares. Based on an average trading volume of 65,900 shares, the short-interest ratio is currently 1.8 days. Approximately 8.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Aptevo Therapeutics to a “sell” rating in a research report on Saturday, March 15th.

Aptevo Therapeutics Price Performance

Shares of Aptevo Therapeutics stock opened at $1.12 on Friday. The company’s 50-day moving average price is $3.32 and its 200-day moving average price is $138.39. Aptevo Therapeutics has a 12-month low of $1.12 and a 12-month high of $180.19.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.